CiPHER logo

CiPHER

Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases

CiPHER

Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases
Funding Sanofi (via CCC)
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status Closed
Start Date 10-Oct-2014

The prognosis for patients with breast cancer and with brain metastases is poor and clinically this represents a patient group with an unmet need. Whilst surgical excision or stereotactic radio Surgery is an option for some patients, this is unfortunately not the case for the majority. These patients either receive pallative external beam radiotherapy or best supportive care.

From in vitro work we know that Cabazitaxel crosses the blood brain barrier and it has also been shown to be effective in metastatic breast cancer in patients who have progressed after anthracycline and taxane treatment. Cabazitaxel is an effective cytotoxic agent that crosses the blood brain barrier and we hope to investigate this attibute in this Phase II study across several UK recruitment centres. Potentially this therapy could afford survival advantage.

Patients on this study will receive Cabazitaxel chemotherapy treatment and pallative radiotherapy will be deferred until evidence of disease progression. These patients will be monitored clinically and radiologically every three and six weeks respectively.

Publications